01 — At a Glance
The Agrochemical Player That’s Fighting Two Bosses: Nature & The Government
- 52-Week High / Low₹1,975 / ₹949
- Q3FY26 Revenue₹410 Cr
- Q3FY26 PAT₹40 Cr
- Q3FY26 EPS (₹)₹8.87
- Annualised EPS (Q3×4)₹35.48
- Book Value (as of Sep’25)₹342
- Price to Book2.94x
- Interest Coverage75.7x
- Debt / Equity0.02x
- FY25 Full-Year EPS₹65.88
Auditor’s Opening Note: Dhanuka Agritech ended Q3FY26 with ₹410 crore revenue (-7.9% YoY), ₹40 crore PAT (-27.3% YoY), and a 28.3% ROCE that hasn’t budged despite two consecutive quarters of volume collapse. The stock has lost 36.6% over 6 months, and management called the performance “a blemish.” A buyback was initiated at peak prices, because apparently if you can’t fix the weather, you might as well buy shares back. The Bayer acquisition is already adding complexity that management is trying to turn into a story. Let’s separate the noise from the actual business.
02 — Introduction
The Farmer’s Best Friend & The Stock Market’s Worst Nightmare. Sometimes Both.
Dhanuka Agritech sells poison — legally, morally, and profitably. Insecticides. Fungicides. Herbicides. Plant growth regulators. The things that keep Indian farms from turning into a four-course buffet for every pest with wings and a bad attitude.
The business model is classically simple: source active ingredients from MNCs (which account for ~50% of revenue), blend them into formulations at four manufacturing plants, distribute through 6,500 distributors and 80,000 retailers, and reach ~10 million farmers across India. In normal years, this prints money. 22% ROE, 28% ROCE, 20% EBITDA margins. The company has delivered consistent double-digit profit growth for a decade.
But Q3FY26 wasn’t a normal year. It was a year where the monsoon forgot to stop, chilli farmers wanted to cry, grape growers filed for bankruptcy, and the government decided biostimulants were suddenly too dangerous to sell. Two consecutive quarters of declining revenue and profit. Management conceded it’s “a blemish.” Investors disagreed and lobbed 36.6% off the stock price in half a year. The board responded by initiating a ₹100 crore buyback at peak prices, which is management-speak for “we think it’s cheap but the market disagrees, so watch us prove a point.”
The twist: the company acquired Bayer AG’s global Iprovalicarb and Triadimenol rights for ₹160 crore, opening pathways to 20+ countries, but that upside is 2–3 years away and won’t show up in FY26 earnings. The near-term story is pure domestic pain. The medium-term story is a potential inflection. Let’s see what actually happened in the quarter.
Concall Reality Check (Feb 2026): Management framed Q3 as an industry-wide volume downcycle and explicitly stated: “the bad phase is over now.” Management then admitted January was “looking well.” The honesty is refreshing. The realism is terrifying. Q4 data will define whether they’re right or just hopeful.
03 — Business Model: Poison Delivery Logistics at ₹10 Million Farmers Per Click
Three-Layer Distribution Network in a Country Where the Last Mile is Literally a Mud Lane
Dhanuka’s competitive moat isn’t secret sauce or patented molecules — it’s distribution depth. The company operates 41 warehouses, 6,500+ distributors, 80,000+ retailers, and reaches ~10 million farmers. This isn’t a market-share story; this is a market-presence story. In agrochemicals, where the buying decision happens at a local retailer’s counter after a monsoon prediction goes wrong, deep retail reach beats advertising. Always.
Product mix tells a different story. Insecticides lead at 46% of revenue, followed by fungicides at 29%, herbicides at 9%, and others at 16%. Three quarters of the portfolio is commoditised — generic off-patent molecules under intense price competition. The remaining quarter is higher-margin partnerships with multinational technical partners (Nissan Chemicals from Japan, others from the USA and Europe). These partnerships account for ~50% of revenue and act as a gross margin cushion.
Revenue geography: South 34%, West 30%, North 25%, East 11%. The south is the stronghold (grapes, horticulture, sugarcane, tobacco). The west is growing (peanuts, cotton, maize). The north is stable (wheat, basmati, pulses). The east is underpenetrated (rice-growing region with lower chemical intensity). Management targets 1.5x–2x market growth via distribution expansion and product innovation.
Four manufacturing plants (Sanand & Dahej in Gujarat, Keshwana in Rajasthan, Udhampur in J&K) serve the domestic formulation business. A new technical manufacturing plant at Dahej is ramping up to absorb the Bayer acquisition molecules and serve contract manufacturing discussions with two multinational agrochemical companies. The technical plant was supposed to be EBITDA-positive in FY26; instead, it burned ₹4 crore in Q3. Management now aims for EBITDA positivity in FY27, assuming 80% capacity utilization with three product candidates.
New Molecule Contribution14.93%FY25 vs 13.29% FY24
Bayer Revenue (India)₹25–27 Cr9M FY26; ₹30 Cr est. FY26
MNC Partnerships10+Japan, USA, Europe
Farmer Reach (millions)~10Via 80,000 retailers
Bayer Deal Deep Dive: Acquisition of Iprovalicarb (CAA fungicide for horticulture) and Triadimenol (seed treatment fungicide) for ₹160 crore opened 20+ countries for India-based formulation and eventual export. NEB (Net Economic Benefit) accounting — a royalty-like structure with “no COGS” — inflated Q3 gross margins by ₹6 crore and 9M by ₹19.5 crore. This is borrowed margin. It will disappear by FY28 once manufacturing and registration transfer completes. Long-term gross margin normalizes to ~38% vs recent 40%. This is material but not catastrophic.
💬 Drop a comment: When a company buys back stock after two bad quarters, is it: (A) brave contrarian conviction, or (B) desperate management speak? What does Dhanuka’s ₹100 crore buyback signal to you?
04 — Financials Overview
Q3 FY26: The Monsoon That Ate Earnings
Result type: Quarterly Results (Q3 FY26 ended Dec 31, 2025) | Q3FY26 EPS: ₹8.87 | Annualised EPS (Q3×4): ₹35.48 | Full-year FY25 EPS: ₹65.88
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 410 | 445 | 598 | -7.9% | -31.6% |
| Operating Profit (EBITDA approx) | 59 | 76 | 137 | -22.4% | -56.9% |
| OPM % | 14% | 17% | 23% | -300 bps | -900 bps |
| PAT | 40 | 55 | 94 | -27.3% | -57.4% |
| EPS (₹) | 8.87 | 12.21 | 20.85 | -27.3% | -57.4% |
P/E Reality Check: Full-year FY25 EPS ₹65.88 ÷ CMP ₹1,015 = P/E 15.41x (screener shows 17.3x, likely because it’s pricing in Q3 & Q4 weakness ahead). If we annualise Q3 (₹8.87 × 4 = ₹35.48), implied P/E is 28.6x — a 50% premium to current trailing. That’s what two bad quarters and a monsoon do to a quality business. The reason the stock has cratered. The reason management thinks buyback is smart.
Margin Bridge (Concall): Gross margin was supported by NEB of ₹6 crore in Q3 and ₹19.5 crore in 9M. Excluding this, gross margins are normalizing downward. Long-term sustainable gross margin = ~38% (vs ~40% recently). The 200 bps step-down is NEB taper as Bayer transition completes. Technical price softening for key intermediates is “almost over now,” per management. No material sourcing disadvantage from China export rebate changes. The message: Q3 margins are distorted, and Q4 should stabilize.
05 — Valuation Discussion: Fair Value Range
What’s A Company Worth When Farmers Won’t Buy What It’s Selling?
